• 제목/요약/키워드: Transitional cell carcinoma

검색결과 47건 처리시간 0.024초

Age at Diagnosis in Bladder Cancer: Does Opium Addiction Play a Role?

  • Karbakhsh, Mojgan;Dabbagh, Najmeh;Shabani, Azadeh;Tabibi, Ali;Akhavizadegan, Hamed
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권8호
    • /
    • pp.4723-4725
    • /
    • 2013
  • Background: Bladder cancer is a major health problem, especially among men. Opium addiction can be an important risk factor. One important question is whether it can affect the age of onset of bladder cancer. We performed this study to evaluate this question. Materials and Methods: In a cross-section study, records of patients diagnosed with bladder carcinoma in Shahid Labbafinejad Medical Center, within 1999-2008 were included. Data were extracted from records regarding age at onset, gender, smoking status, and opioid addiction and analyzed with SPSS 13. Results: Within 10 years, 920 cases were diagnosed with bladder cancer of which 97 percent were transitional cell carcinoma. In 698 cases, opium addiction status was recorded in 21.3% (n=149). Age at diagnosis was $59.7{\pm}11.51$ (median: 60) among opioid addicts which was significantly lower than nonaddicts ($63.1{\pm}13.65$, Median: 65) (P<0.001). Conclusions: Opium addiction can decrease the age of onset of bladder cancer.

No Relationship between the Amount of DNA Damage and the Level of hMLH1 and RASSF1A Gene Expression in Bladder Cancer Cells Treated with Cisplatin and Gemcitabine

  • de Camargo, Elaine Aparecida;da Silva, Glenda Nicioli;Gobette, Camila Pereira;de Castro Marcondes, Joao Paulo;Salvadori, Daisy Maria Favero
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권10호
    • /
    • pp.5941-5948
    • /
    • 2013
  • Tumor response to antineoplastic drugs is not always predictable. This is also true for bladder carcinoma, a highly recurrent neoplasia. Currently, the combination of cisplatin and gemcitabine is well accepted as a standard protocol for treating bladder carcinoma. However, in some cases, this treatment protocol causes harmful side effects. Therefore, we investigated the roles of the genes TP53, RASSF1A (a tumor suppressor gene) and hMLH1 (a gene involved in the mismatch repair pathway) in cell susceptibility to cisplatin/gemcitabine treatment. Two bladder transitional carcinoma cell (TCC) lines, RT4 (wild-type TP53) and 5637 (mutated TP53), were used in this study. First, we evaluated whether the genotoxic potential of cisplatin/gemcitabine was dependent on TP53 status. Then, we evaluated whether the two antineoplastic drugs modulated RASSF1A and hMLH1 expression in the two cell lines. Increased DNA damage was observed in both cell lines after treatment with cisplatin or gemcitabine and with the two drugs simultaneously, as depicted by the comet assay. A lack of RASSF1A expression and hypermethylation of its promoter were observed before and after treatment in both cell lines. On the other hand, hMLH1 downregulation, unrelated to methylation status, was observed in RT4 cells after treatment with cisplatin or with cisplatin and gemcitabine simultaneously (wild-type TP53); in 5637 cells, hMLH1 was upregulated only after treatment with gemcitabine. In conclusion, the three treatment protocols were genotoxic, independent of TP53 status. However, cisplatin was the most effective, causing the highest level of DNA damage in both wild-type and mutated TP53 cells. Gemcitabine was the least genotoxic agent in both cell lines. Furthermore, no relationship was observed between the amount of DNA damage and the level of hMLH1 and RASSF1A expression. Therefore, other alternative pathways might be involved in cisplatin and gemcitabine genotoxicity in these two bladder cancer cell lines.

내측상악부분절제술의 임상적 고찰 (A Clinical Study of Medial Maxillectomy)

  • 조승호;김형태;김민식;선동일;박영학;정민교
    • 대한두경부종양학회지
    • /
    • 제13권1호
    • /
    • pp.40-44
    • /
    • 1997
  • Background: Lateral rhinotomy and medial maxillectomy, an en bloc resection of the medial maxillary sinus, ethmoid sinus with the lamina papyracea, medial orbital floor, and lacrimal fossa-duct, have been advocated for lateral nasal wall neoplasms as a standard approach method. Objective: This report was conducted to investigate the clinical efficacy of lateral rhinotomy and medial maxillectomy for lateral nasal wall neoplasms. Materials and Methods: We retrospectively analyzed clinical data of 31 patients who were treated at department of otolaryngology-head and neck surgery, Catholic university of Korea, school of medicine between 1990 and 1996. Results: Twenty five patients had benign lesions(80.6%). By far, the largest percentage was inverted papillomas(80%, 20/25). Of the six malignant lesions(19.4%), 33.3%(2/6) was squamous cell carcinoma and other lesions were metastatic renal cell carcinoma, adecarcinoma, transitional cell cacinoma, and hemangiopericytoma. There were a 4% recurrence for benign tumors(1/25), 5% especially for inverted papilloma(1/20), and 50% for malignant neoplasms(3/6). The overall complication rate was 9.7%. Conclusion: Despite the various approach for treatment of lateral nasal wall neoplasms including inverted papilloma, we continue to advocate a lateral rhinotomy and medial maxillectomy as the treatment of choice.

  • PDF

KNOCKDOWN OF IGF-1R BY ANTISENSE OLIGODEOXYNUCLEOTIDE AUGUMENTS THE SENSITIVITY OF BLADDER CANCER CELLS TO MMC

  • Wu, Shu-Fang;Sun, Hong-Zhi;Tu, Zeng-Hong
    • 한국독성학회:학술대회논문집
    • /
    • 한국독성학회 2001년도 International Symposium on Dietary and Medicinal Antimutgens and Anticarcinogens
    • /
    • pp.203-204
    • /
    • 2001
  • Background and Aim: Transitional cell carcinoma (TCC) of the bladder represents the fifth most prevalent malignancy in Western population, with peak incidence found in males of the 50- to 70-year-old age group. A major problem in the management of bladder cancer is the low sensitivity of a large proportion (approximately 40%) among bladder tumors to chemotherapy and the high risk for recurrence of bladder tumors after transurethral resection.(omitted)

  • PDF

방광암에서 p53 Rb 의 면역조직화학적 연구 (Immunohistochemical study on the p53 and Rb In bladder tumor)

  • 이광주;이명환;윤내영
    • 한국수의병리학회지
    • /
    • 제2권2호
    • /
    • pp.85-94
    • /
    • 1998
  • This study was performed to evaluate whether the loss or overexpression of Rb, and overexpression of p53 were prognostic indicators for bladder neoplasia, 52 tumor specimens from transitional cell carcinoma of the urinary bladder were from 42 male and 10 female patients whose age ranged from 30 to 83 years old(mean age; 63,5 years old), This group included 36 superficial and 16 invasive stage bladder tumors, and grades 16-25, p53 was significantly associated with tumor stage and grade(p<0,05 in each), but not with tumor recurrence. Loss of Rb gene expression or Rb overexpression was correlated with stage, but not grade. These results suggested that changes of Rb and p53 expression might play an important role in assessing the aggressiveness of human neoplasms.

  • PDF

혈뇨 환자의 방광암 진단에서 $UBC^{TM}$ (Urinary Bladder Cancer) 검사의 유용성 (Usefulness of the $UBC^{TM}$ (Urinary Bladder Cancer) Test Compared to Urinary Cytology for Transitional Cell Carcinoma of the Bladder in Patients with Hematuria)

  • 길명철;강도영;성열근;정세일;권헌영;정경우;김덕규;노미숙;황태호;윤진한
    • 대한핵의학회지
    • /
    • 제35권3호
    • /
    • pp.192-197
    • /
    • 2001
  • 목적: 요세포검사와 방광경검사는 방광이행상피세포암을 진단하는데 유용한 방법이다. 그러나 요세포검사는 숙련된 검사자가 필요하고 현미경검사상 다양한 해석이 가능할 수 있고 방광경검사는 침습적인 방법이다. $UBC^{TM}$ 검사는 방광암의 상피세포로부터 방출되는 특정한 cytokeratin의 분절에 대한 에피토프를 검출하는 면역방사계수측정법이다. 우리는 방광이행상피세포암의 진단에서 요세포검사와 $UBC^{TM}$ 검사를 비교하여 $UBC^{TM}$ 검사의 유용성을 알아보았다. 대상 및 방법: 혈뇨를 주소로 내원한 84예를 대상으로 중간뇨를 이용하여 $UBC^{TM}$ 검사 (IDL Biotech, Sweden)를 시행하였다. 19예는 방광경검사와 경요도방광종양절제술로 방광이행상피세포암으로 진단되었고(암환자군), 나머지례는 대조군으로 하였다. $UBC^{TM}$ 검사상 결과가 $12{\mu}g/L$ 이상인 경우를 양성으로 하였다. 결과: UBC 검사 결과는 암환자군과 대조군에서 각각 $95.9{\pm}166.4{\mu}g/L$$19.2{\pm}85.6{\mu}g/L$ (p<0.001)로 의미있는 차이를 보였다. 방광이행상피세포암에 대한 UBC 검사와 요세포검사의 민감도는 각각 89.5% (17/19), 47.4% (9/19) (p<0.05)였고, 특이도는 각각 81.5% (53/65)와 100% (65/65)였다. $UBC^{TM}$ 검사는 stage Ta, $T_1$ (84.6 vs 38.5 %, p<0.05)과 grade I (83.3% vs 16.7%, p<0.05)에서 요세포검사보다 더 유의하였다. $UBC^{TM}$ 검사의 결과는 세포분화도가 더 나빠질수록 증가하는 경향을 보였다 (Grade I : 83.3%, Grade II : 90%, Grade III : 100%). 결론: $UBC^{TM}$ 검사는 다른 비뇨기과적 질환과 방광이행상피세포암을 구별하는데 유용한 방법으로 사료된다. 특히 $UBC^{TM}$ 검사는 초기 방광이행상피세포암과 세포분화도가 좋은 방광암을 진단하는데 있어 간편하고, 비침습적이며 요세포 검사보다 높은 민감도를 갖는 것으로 분석되어 요세포검사의 낮은 민감도를 보완하는 유용한 선별검사의 하나로 선택하여도 좋을 것으로 사료된다.

  • PDF

상부 요로상피암에서 신보조 항암요법 및 보조 항암요법의 최신 지견 (Update on Current Role of Perioperative Chemotherapy in Upper Tract Urothelial Carcinoma)

  • 전병조;태범식;박재영
    • 대한비뇨기종양학회지
    • /
    • 제16권3호
    • /
    • pp.89-96
    • /
    • 2018
  • Upper tract urothelial carcinoma (UTUC) has a relatively low prevalence rate of about 1.8 per 100,000 people. According to the recent literature, the development of diagnostic techniques has gradually increased the prevalence and diagnosis rate. In the past, when UTUC was diagnosed, more than 60% of the patients were diagnosed as locally advanced or metastatic cancer. However, since 2010, approximately 70% of the patients have been diagnosed as operable stage. Although radical nephroureterectomy is known as the basis of treatment for UTUC, overall survival is poor in patients with lymph node invasion. Especially, the finding that a localized UTUC is associated with a high risk of cancer metastasis in approximately 50% of patients suggests that these patients may not have sufficient treatment through surgery alone. The European Association of Urology and the National Comprehensive Cancer Network guideline 2017 suggested that postoperative adjuvant chemotherapy may be considered in patients with advanced UTUC beyond pT2. Also, recent meta-analyses have reported that cisplatin-based adjuvant chemotherapy can be expected to have a synergistic effect of overall survival and disease-free survival. However, many patients with UTUC undergo postoperative renal failure, which may result in failure to perform cisplatin-based adjuvant chemotherapy with adequate dose. For this reason, several researchers have suggested that it is beneficial to apply neoadjuvant chemotherapy when the preoperative renal function is maintained to a certain extent. But, neoadjuvant chemotherapy has not been used by many clinicians because of the lack of studies and the rarity of the disease. We are currently discussing the outcomes and prospects of perioperative chemotherapy.

Retrospective Evaluation of Risk Factors and Immunohistochemical Findings for Pre-Neoplastic and Neoplastic lesions of Upper Urinary Tract in Patients with Chronic Nephrolithiasis

  • Desai, Fanny Sharadkumar;Nongthombam, Jitendra;Singh, Lisam Shanjukumar
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권18호
    • /
    • pp.8293-8298
    • /
    • 2016
  • Background: Urinary stones are known predisposing factors for upper urinary tract carcinoma (UUTC) which are commonly detected at advanced stage with poor outcome because of rarity and lack of specific criteria for early detection. Aims and objectives: The main aim was to evaluate the impact of age, gender andstone characteristics on risk of developing UUTC in patients with chronic nephrolithiasis. We also discuss the role of aberrant angiogenesis (AA) and immunohistochemical expression of p53, p16INK4a, CK20 and Ki-67 in diagnosis of pelvicalyceal neoplastic (NL) and pre-neoplastic lesions (PNL) in these patients. Materials and Methods: Retrospective analysis of pelvicalyceal urothelial lesions from 88 nephrectomy specimens were carried out in a tertiary care centre from June 2012 to December 2014. Immunohistochemistry (IHC) was performed on 37 selected cases. Computed image analysis was performed to analyse aberrant angiogenesis. Results: All UUTC (5.7%) and metaplastic lesions were found to be associated with stones. Some 60% were pure squamous cell carcinoma and 40% were transitional cell carcinoma. Odd ratios for developing NL and PNL lesions in presence of renal stone, impacted stones, multiple and large stag horn stones were 9.39 (95% CI 1.15-76.39, p value 0.05), 6.28 (95% CI 1.59-24.85, p value 0.000) and 7.4 (95% CI, 2.29-23.94, p value 0.001) respectively. When patient age was ${\geq}55$, the odds ratio for developing NL was 3.43 (95% CI 1.19-9.88, p value 0.019). IHC analysis showed that mean Ki-67 indices were $3.15{\pm}3.63%$ for non-neoplastic lesions, $10.0{\pm}9.45%$ for PNL and $28.0{\pm}18.4%$ for NL. Sensitivity and specificity of CK20, p53, p16INK4a, AA were 76% and 95.9%; 100% and 27.5%; 100% and 26.5%; 92.3 % and 78.8% respectively. Conclusions: Age ${\geq}55years$, large stag horn stones, multiple stones and impacted stones are found to be associated with increased risk of NL and PNL in UUT. For flat lesions, a panel of markers, Ki 67 index >10 and presence of aberrant angiogenesis were more useful than individual markers.

SPF Ktc : ICR 마우스의 자연발생 종양에 대한 병리학적 연구 (A pathological study of spontaneous tumors in SPF Ktc : ICR mice)

  • 손화영;강부현;한상섭;전무형;조성환
    • 대한수의학회지
    • /
    • 제32권4호
    • /
    • pp.609-627
    • /
    • 1992
  • The study was carried out to obtain the basic data for types, incidence and histopathological features of the spontaneous tumors of the specific pathogen free (SPF) Ktc : ICR mice bred in a barrier system in Technology Research Center, Korea Research Institute of Chemical Technology. One hundred of the mice consisted of 50 males and 50 females were examined for 18 months. 1. The overall incidence rate of spontaneous tumors was 51(51%) of 100 heads tested. The male mice showed slightly higher incidence(28%) than the female(23%), and the incidence rate and the number of affected organs were increased with the increasing age of mice. 2. The incidence rate of primary tumor was 59(59%) of 100 heads tested, consisted of 30 cases (50.8%) of benign tumors and 29 cases(49.2%) of malignant tumors. Among the malignant tumors twenty cases were metastasized to various organs. 3. In tumor incidence rates by systems and organs, the male mice showed the high incidence rate in the liver (18%), hematopoietic system (16% ) and lung (14%), while the female mice, in the hematopoietic system(18%), lung(12%), liver(8%) and uterus(8%). 4. The tumors showing the particularly low incidence rates (<1.0%) were rhabdomyosarcoma in the skeletal muscle, malignant schwannoma in the peripheral nerve, cortical adenoma in the adrenal gland, transitional cell carcinoma in the urinary bladder, tubular cell adenoma in the kidney and adenoma in the pituitary gland and harderian gland.

  • PDF

Genomic characterization of clonal evolution during oropharyngeal carcinogenesis driven by human papillomavirus 16

  • Chae, Jeesoo;Park, Weon Seo;Kim, Min Jung;Jang, Se Song;Hong, Dongwan;Ryu, Junsun;Ryu, Chang Hwan;Kim, Ji-Hyun;Choi, Moon-Kyung;Cho, Kwan Ho;Moon, Sung Ho;Yun, Tak;Kim, Jong-Il;Jung, Yuh-Seog
    • BMB Reports
    • /
    • 제51권11호
    • /
    • pp.584-589
    • /
    • 2018
  • Secondary prevention via earlier detection would afford the greatest chance for a cure in premalignant lesions. We investigated the exomic profiles of non-malignant and malignant changes in head and neck squamous cell carcinoma (HNSCC) and the genomic blueprint of human papillomavirus (HPV)-driven carcinogenesis in oropharyngeal squamous cell carcinoma (OPSCC). Whole-exome (WES) and whole-genome (WGS) sequencing were performed on peripheral blood and adjacent non-tumor and tumor specimens obtained from eight Korean HNSCC patients from 2013 to 2015. Next-generation sequencing yielded an average coverage of $94.3{\times}$ for WES and $35.3{\times}$ for WGS. In comparative genomic analysis of non-tumor and tumor tissue pairs, we were unable to identify common cancer-associated early mutations and copy number alterations (CNA) except in one pair. Interestingly, in this case, we observed that non-tumor tonsillar crypts adjacent to HPV-positive OPSCC appeared normal under a microscope; however, this tissue also showed weak p16 expression. WGS revealed the infection and integration of high-risk type HPV16 in this tissue as well as in the matched tumor. Furthermore, WES identified shared and tumor-specific genomic alterations for this pair. Clonal analysis enabled us to infer the process by which this transitional crypt epithelium (TrCE) evolved into a tumor; this evolution was accompanied by the subsequent accumulation of genomic alterations, including an ERBB3 mutation and large-scale CNAs, such as 3q27-qter amplification and 9p deletion. We suggest that HPV16-driven OPSCC carcinogenesis is a stepwise evolutionary process that is consistent with a multistep carcinogenesis model. Our results highlight the carcinogenic changes driven by HPV16 infection and provide a basis for the secondary prevention of OPSCC.